ISCD Learning
March 2027 - Quality Bone Densitometry: Performance, Interpretation, and Clinical Application for Clinicians
Includes Multiple Live Events. The next is on 03/13/2027 at 10:00 AM (EST)
-
Register
- Non-Member - $975
- Full Member - $675
- Clinician Member - $675
- Technologist Member - $675
- Resident/Student/Fellow/Retired Membership - $675
- MOC Only - $975
- Community Member - $675
- Professional Member - $675
Course Date
March 13 & 14, 2027.
Course Description
The core elements of this course serve to educate healthcare providers about bone densitometry and osteoporosis and to apply standard practices to assure quality performance and interpretation of bone densitometry studies. The course is offered in two parts. The first day sets the standard to perform Quality DXA interpretation. Day 2 focuses on the clinical assessment, prevention, treatment and management of osteoporosis and the essential role that high-quality DXA plays in treatment initiation decisions and monitoring of osteoporotic patients.
Target Audience
The course is most appropriate for those involved in the performance and interpretation of DXA scans and those managing patients with osteoporosis. It is open to MDs, PhDs, DOs, Nurse Practitioners, and Physician Assistants. Technologists may attend if they have previously taken the ISCD Quality Bone Densitometry for Technologists course.
Learning Objectives
After attending the course, participants should be better prepared to:
- Describe appropriate clinical evaluation of patients at risk for fragility fracture.
- Summarize the value and importance of quality bone densitometry for the diagnosis of osteoporosis, assessment of fracture risk, and monitoring of BMD.
- Recognize errors in DXA analysis and reporting.
- Explain new and emerging guidelines that provide evidence-based information regarding skeletal health.
- Describe the use of current and new pharmacologic therapies for the management and treatment of osteoporosis, including adverse effects.
Method of Participation
This activity will be offered live streamed via Zoom, allowing the learner to watch and ask questions in a live format on March 13 & 14, 2027. The course will NOT be recorded for future viewing, so attendees must be present during the scheduled times. Learners will be asked to complete a post-course survey to indicate what they will change in their practice as a result of this activity.
Rates
Cancellation Policy
Attendee Cancellation Policy All changes in registration must be made in writing to [email protected]. Cancellations received 30 days prior to the start of the program are eligible for a full refund minus a $50 administrative fee. Cancellations received less than 30 days prior to the start of the course will not be refunded.
Course Changes or Cancellations ISCD reserves the right to cancel the program, change dates and/or meeting location. If a program is canceled, all program fees will be refunded automatically unless the registered participant elects to transfer to another program. Participants will be notified of any changes within 21 days of the course start date.
ACCME Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISCD. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA PRA Category 1 Credit(s)™
This activity is under review for accreditation by Amedco LLC targeting a maximum of 13.00 AMA PRA Category 1 CreditsTM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Deadline to Claim Credit
Participants will have 90 days from the live activity end date to complete the activity survey and claim continuing education credit. The last day to claim credit or access materials for this course is June 15, 2027 @ 11:00pm EDT.
Schedule - Saturday, March 13, 2027 - All times Eastern Time (NYC/USA)
Schedule - Sunday, March 14, 2027 - All times Eastern Time (NYC/USA)
Vidushi Sood, MD
Endocrinologist and Clinical Associate Professor
UW Health, Department of Medicine at the University of Wisconsin School of Medicine and Public Health
Vidushi Sood, MD, is a UW Health endocrinologist and a clinical associate professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health. She cares for patients with a range of hormone-related disorders and bone health issues.
Dr. Sood commonly treats hormonal conditions originating in the thyroid, adrenal and pituitary glands. These can include diabetes, thyroid and pituitary disease, beta thyroid disease (genetic condition that affects hormones), ovarian and testicular disease and bone health disorders. She has special clinical interests in osteoporosis (bone weakening) and polycystic ovarian syndrome, or PCOS (ovaries produce unusually high levels of male sex hormones, which can make getting pregnant challenging).
Dr. Sood personalizes care to meet each patient’s needs. She listens carefully to understand their concerns and goals and offers education about conditions and treatment options. She takes a comprehensive, holistic approach to care, addressing all her patients’ concerns to improve their health and wellness. She enjoys helping people feel better and finds it particularly rewarding to help people sleep better or become pregnant, for example.
E. Michael Lewiecki, MD, FACP, FACE, CCD
Director
New Mexico Clinical Research & Osteoporosis Center, Inc.
Dr. Lewiecki is Director of New Mexico Clinical Research & Osteoporosis Center and Director of Bone Health ECHO at University of New Mexico Health Sciences Center in Albuquerque, NM. He is a consultant in osteoporosis and other metabolic bone diseases, supervisor and interpreter of bone density studies, and an educator with a special interest in the evaluation and treatment of osteoporosis and metabolic bone diseases. He has been principal investigator for many osteoporosis clinical trials and is author of over 390 publications in peer-reviewed medical journals with more than 45,000 citations, as well as books, book chapters, and online publications. He is past president of the International Society for Clinical Densitometry (ISCD) and founding president of the Osteoporosis Foundation of New Mexico (OFNM). He is program director of the annual Santa Fe Bone Symposium, the flagship activity of the OFNM. He is Review Editor for Osteoporosis International and is on the editorial board of the Journal of Clinical Densitometry. He has participated with development of ISCD Official Positions (2002, 2004, 2006, 2008, 2011, 2013, 2015, 2019, 2023), International Workshops on the Evaluation and Management of Primary Hyperparathyroidism (2009, 2014, 2022), and osteoporosis treatment guidelines of the National Osteoporosis Foundation / Bone Health & Osteoporosis Foundation (2008, 2014, 2022) and the American Association of Clinical Endocrinologists (2016, 2020), as well as with many other workshops and consensus statements in the field of metabolic bone disease. He has received national and international awards that include the 2021 “Dr. John P. Bilezikian ISCD Global Leadership Award”, and the 2021 “Lawrence G. Raisz Memorial Lecture Award” with the Bone Health & Osteoporosis Foundation, and the 2025 “Santa Fe Bone Symposium Award” in recognition of pioneering contributions to improving skeletal health. He was listed by Expertscape as the #1 osteoporosis expert in the world during the years 2011-2021. ScholarGPS currently lists him as #3 worldwide osteoporosis scholar for the previous 5 years.
Alvin Lee Day, MD, RhMSUS, CCD
Rheumatologist, Clinical Assistant Professor of Medicine
Prisma Health in the Midlands, University of South Carolina Floyd School of Medicine
Alvin Lee Day, MD, RhMSUS, CCD, is a rheumatologist at Prisma Health in the Midlands and a Clinical Assistant Professor of Medicine at the University of South Carolina Floyd School of Medicine. He received his medical degree from the University of South Carolina Floyd School of Medicine, completed his residency in internal medicine at Prisma Health–Midlands and completed a fellowship in rheumatology at UAB Hospital in Birmingham, Alabama.
His academic interests include general rheumatology, musculoskeletal ultrasound, osteoporosis and metabolic bone diseases, quality bone densitometry, and performing arts medicine. He is active in the International Society for Clinical Densitometry where he serves as the membership, marketing, and communications committee chair. Dr. Day is a co-author of the Manual of Musculoskeletal Ultrasound: A Self-Study, Protocol-Based Approach and is the director of the rheumatology bone health clinic at Prisma Health.
Statement of Independence
The ISCD maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the ISCD provide in-depth presentations that are fair, balanced, independent, and scientifically rigorous. ISCD requires faculty, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ISCD for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Individual disclosures are included in the course material. No Commercial Support has been provided for this activity.
Disclaimer
The information and suggestions presented at the courses, seminars and other programs sponsored by ISCD and other collaborating societies are subject to change and therefore should serve only as a foundation for further investigation and study. Any forms presented at our seminars or programs are samples only and are not necessarily authoritative. All information, procedures, and forms contained or used in such seminars or programs should serve only as a guide for use in specific situations.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. ISCD does not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for a discussion of approved indications, contraindications, and warnings.
Privacy & Confidentiality Statement
The ISCD will record the learner’s personal information as provided on evaluations to allow for the issuance and tracking of CME/CE certificates. The ISCD may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its educational program. No individual performance data or any other personal information collected for evaluations will be shared with third parties.
Attendance Cancellation Policy
All changes in registration must be made in writing to [email protected]. Cancellations received 30 days prior to the start of the program are eligible for a full refund minus a $50 administrative fee. Cancellations received less than 30 days prior to the start of the course will not be refunded.
Course Changes or Cancellations
ISCD reserves the right to cancel the program, change dates, how the course is taught, and/or meeting location. If a program is canceled, all program fees will be refunded unless the registered participant elects to transfer to another program. Participants will be notified of any changes within 21 days of the course start date.
